相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pyridoxine Is Not Effective to Prevent Hand-Foot Syndrome Associated With Capecitabine Therapy: Results of a Randomized, Double-Blind, Placebo-Controlled Study
Yoon-Koo Kang et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer
A. F. C. Okines et al.
ANNALS OF ONCOLOGY (2009)
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial
Y. -K. Kang et al.
ANNALS OF ONCOLOGY (2009)
Prophylactic ciprofloxacin treatment prevented high mortality, and modified systemic and intestinal immune function in tumour-bearing rats receiving dose-intensive CPT-11 chemotherapy
H. Xue et al.
BRITISH JOURNAL OF CANCER (2009)
Hand-Foot Syndrome (Hand-Foot Skin Reaction, Palmar-Plantar Erythrodysesthesia): Focus on Sorafenib and Sunitinib
Adam D. Lipworth et al.
ONCOLOGY (2009)
Clinical Significance of Skin Toxicity due to EGFR-Targeted Therapies
Monica Giovannini et al.
JOURNAL OF ONCOLOGY (2009)
Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer.: EORTC study 40015
C.-H. Koehne et al.
ANNALS OF ONCOLOGY (2008)
Candidate mechanisms for capecitabine-related hand-foot syndrome
Gerard Milano et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Matched case-control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot
Florian Scotte et al.
CANCER (2008)
Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines?
Jane L. Yen-Revollo et al.
CLINICAL CANCER RESEARCH (2008)
Atypical Hand-and-Foot syndrome in an African American Patient treated with Capecitabine with normal DPD activity: Is there an ethnic disparity?
Muhammad Wasif Saif et al.
CUTANEOUS AND OCULAR TOXICOLOGY (2008)
Capecitabine and oxaliplatin for advanced esophagogastric cancer
David Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Evolving Strategies for the Management of Hand-Foot Skin Reaction Associated with the Multitargeted Kinase Inhibitors Sorafenib and Sunitinib
Mario E. Lacouture et al.
ONCOLOGIST (2008)
Role of cytokines (TNF-α, IL-1β and KC) in the pathogenesis of CPT-11-induced intestinal mucositis in mice:: effect of pentoxifylline and thalidomide
Maria Luisa P. Melo et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C study
Charles S. Fuchs et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A phase I trial of RX-0201 (AKT anti-sense) in patients with an advanced cancer
J. Marshall et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Localized palmar-plantar epidermal hyperplasia: A previously undefined dermatologic toxicity to sorafenib
Matthew Beldner et al.
ONCOLOGIST (2007)
Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: A planned safety analysis in 1,864 patients
Hans-Joachim Schmoll et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Activity and substrate specificity of pyrimidine phosphorylases and their role in fluoropyrimidine sensitivity in colon cancer cell lines
Olaf H. Temmink et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2007)
St. John's wort attenuates irinotecan-induced diarrhea via down-regulation of intestinal pro-inflammatory cytokines and inhibition of intestinal epithelial apoptosis
Ze-Ping Hu et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2006)
Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians
Lori Kay Mattison et al.
CLINICAL CANCER RESEARCH (2006)
Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: Expression analysis of genes related to outcome
MW Saif et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Capecitabine as adjuvant treatment for stage III colon cancer
C Twelves et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer
I Chau et al.
ANNALS OF ONCOLOGY (2005)
Lack of contribution of dihydrofluorouracil and α-fluoro-β-alanine to the cytotoxicity of 5′-deoxy-5-fluorouridine on human keratinocytes
JL Fischel et al.
ANTI-CANCER DRUGS (2004)
Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial
W Scheithauer et al.
ANNALS OF ONCOLOGY (2003)
Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer
JY Douillard et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer
J Carmichael et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
First-line oral capecitabine therapy in metastatic colorectal cancer:: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin
J Cassidy et al.
ANNALS OF ONCOLOGY (2002)
Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: A single-institution experience
S Abushullaih et al.
CANCER INVESTIGATION (2002)
Muco-cutaneous changes during long-term therapy with hydroxyurea in chronic myeloid leukaemia
C Vassallo et al.
CLINICAL AND EXPERIMENTAL DERMATOLOGY (2001)
分享论文
